There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Insulin resistance is a cardinal feature of type 2 diabetes and is characteristic
of a wide range of other clinical and experimental settings. Little is known about
why insulin resistance occurs in so many contexts. Do the various insults that trigger
insulin resistance act through a common mechanism? Or, as has been suggested, do they
use distinct cellular pathways? Here we report a genomic analysis of two cellular
models of insulin resistance, one induced by treatment with the cytokine tumour-necrosis
factor-alpha and the other with the glucocorticoid dexamethasone. Gene expression
analysis suggests that reactive oxygen species (ROS) levels are increased in both
models, and we confirmed this through measures of cellular redox state. ROS have previously
been proposed to be involved in insulin resistance, although evidence for a causal
role has been scant. We tested this hypothesis in cell culture using six treatments
designed to alter ROS levels, including two small molecules and four transgenes; all
ameliorated insulin resistance to varying degrees. One of these treatments was tested
in obese, insulin-resistant mice and was shown to improve insulin sensitivity and
glucose homeostasis. Together, our findings suggest that increased ROS levels are
an important trigger for insulin resistance in numerous settings.